{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.12","upperLimit":"21.45","value":"15.8"},{"groupId":"OG001","lowerLimit":"12.25","upperLimit":"23.04","value":"17.2"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.10","upperLimit":"60.03","value":"53.1"},{"groupId":"OG001","lowerLimit":"53.23","upperLimit":"67.06","value":"60.3"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.99","upperLimit":"8.02","value":"4.3"},{"groupId":"OG001","lowerLimit":"1.71","upperLimit":"7.58","value":"3.9"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.89","upperLimit":"17.15","value":"12.0"},{"groupId":"OG001","lowerLimit":"5.70","upperLimit":"14.16","value":"9.3"}]}],"title":"PD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.06","upperLimit":"6.14","value":"2.9"},{"groupId":"OG001","lowerLimit":"0.01","upperLimit":"2.70","value":"0.5"}]}],"title":"Unable to Evaluate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.89","upperLimit":"17.15","value":"12.0"},{"groupId":"OG001","lowerLimit":"5.31","upperLimit":"13.59","value":"8.8"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"BOR: best response for a participant, observed during assessment period according to modified response criteria for iNHL (Modified Cheson et al, 2007). CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in size of other nodes, liver, or spleen; with exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present, SD: Failing to attain criteria needed for a CR or PR, but not fulfilling those for PD, PD: appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size; at least a 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or hepatic nodules).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"NUMBER","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who had reached the end of induction treatment response assessment.","reportingStatus":"POSTED","timeFrame":"Baseline until end of induction treatment (assessed at baseline, 14 days prior to Cy 4 Day 1 [1 Cy=28days], 28-42 days after Cy 6 Day 1)","title":"Percentage of Participants With BOR at the End of Induction Treatment as Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}